Vivani Medical, Inc.
NASDAQ:VANIMedical - Devices
+$0.02 today
- Market cap
- $94.71M
- Beta
- 3.29
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.33
Volume 0.18M
Average 0.24M
VANI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Vivani Medical, Inc.NASDAQ: VANI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $6.78M (cash outflow) rose 7.6% year over year, behind the +14.1% change in trailing-twelve-month net income. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +24.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$20.59M (-22.6%) for the fiscal year ending Dec 2026, a slowdown from the +13.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.78M+2.2% QoQ
- Last fiscal yearDec 2025
- -$26.61M+13.3% YoY
- LTMMar 2026
- -$27.09M+14.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.6% | -3.3% | -10.9 pp |
| 1 year | +13.3% | -22.6% | -35.9 pp |
| 3-year CAGR | +24.2% | +0.3% | -23.9 pp |
| 5-year CAGR | -2.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (26.61M) USD
- Year-over-year change
- -13.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.61M) | -13.3% |
| FY2024 | 2024-12-31 | (23.49M) | +8.4% |
| FY2023 | 2023-12-31 | (25.65M) | -84.7% |
| FY2022 | 2022-12-31 | (13.89M) | -8.7% |
| FY2021 | 2021-12-31 | (12.77M) | — |
Net Income vs competitors
How VANI compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.1% is the 3rd highest of 8, against a peer median of +1.7%.
- Over three fiscal years its annual growth of +24.2% compares with a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $45.34M USD | -20.5% | +22.1% | 62.7% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
| LTM Mar 2026 | CA$36.38M CAD | +1.7% | +3.0% | — | |
| LTM Mar 2026 | $34.78M USD | -13.7% | -21.4% | 226.9% | |
| LTM Mar 2026 | $27.09M USD | +14.1% | +24.2% | — | |
| LTM Mar 2026 | $14.21M USD | +21.8% | -0.1% | 13535.2% | |
| LTM Mar 2026 | $8.27M USD | -11.1% | -14.8% | 7.8% | |
| Peer median (excluding VANI) | — | +1.7% | -4.4% | 144.8% | |
Competitors are the stored peer set for VANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.77M) | (13.89M) | (25.65M) | (23.49M) | (26.61M) |
| Depreciation & Amortization | 345K | 381K | 357K | 400K | 424K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.67M | 1.3M | 1.86M | 1.61M | 1.48M |
| Change in Working Capital | 436K | 338K | (1.29M) | 354K | 229K |
| Accounts Receivables | 0 | 0 | 0 | 0 | (401K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13K | (1.94M) | (602K) | 248K | (222K) |
| Other Working Capital | 423K | 2.28M | (691K) | 106K | 852K |
| Other Non-Cash Items | (627K) | (6.91M) | 1.03M | 336K | 152K |
| Operating Cash Flow | (10.95M) | (18.79M) | (23.7M) | (20.79M) | (24.32M) |
| Capital Expenditures | (572K) | (338K) | (887K) | (556K) | (1.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (572K) | (338K) | (887K) | (556K) | (1.17M) |
| Debt Repayment | 0 | 8M | 0 | 19.05M | 11K |
| Common Stock Issued | 11.62M | 16K | 133K | 18.82M | 23.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (28K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 55.37M | 0 | (18.82M) | 0 |
| Financing Cash Flow | 11.62M | 63.39M | 133K | 19.05M | 23.27M |
| Effect of Forex Changes | (1.1M) | (1K) | 3K | (14K) | 99K |
| Net Change in Cash | 97K | 44.26M | (24.45M) | (2.3M) | (2.12M) |
| Free Cash Flow | (11.52M) | (19.13M) | (24.59M) | (21.34M) | (25.49M) |
Vivani Medical, Inc.
NASDAQ:VANI
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.